LTR Pharma (Australia) Insiders

LTR Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2146) % which means that it has lost $0.2146 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3247) %, meaning that it generated substantial loss on money invested by shareholders. LTR Pharma's management efficiency ratios could be used to measure how well LTR Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Liabilities And Stockholders Equity is likely to gain to about 38.9 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 459.8 K in 2026. Common Stock Shares Outstanding is likely to drop to about 162.5 M in 2026. Net Loss is likely to drop to about (5.3 M) in 2026LTR Pharma maintains a total of 181.73 Million outstanding shares. LTR Pharma holds large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

LTR Pharma Workforce Comparison

LTR Pharma Benchmark Summation

LTR Pharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as LTR Pharma often depends on how effective the management is. LTR Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of LTR management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the LTR management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in LTR Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of LTR Pharma. Check LTR Pharma's Beneish M Score to see the likelihood of LTR Pharma's management manipulating its earnings.

When running LTR Pharma's price analysis, check to measure LTR Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LTR Pharma is operating at the current time. Most of LTR Pharma's value examination focuses on studying past and present price action to predict the probability of LTR Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LTR Pharma's price. Additionally, you may evaluate how the addition of LTR Pharma to your portfolios can decrease your overall portfolio volatility.